Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

“Instead of counting how many people taking the

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 154848
(Total Views: 470)
Posted On: 05/02/2020 10:06:11 AM
Avatar
Posted By: ClosetInvestor
Re: Northstar42 #31456
“Instead of counting how many people taking the drug were kept alive on ventilators or died, among other measures, the National Institute of Allergy and Infectious Diseases said it would judge the drug primarily on a different outcome: how long it took surviving patients to recover.”

There is little doubt in my mind that Gilead heavily influenced the decision to change the endpoint in this trial despite Gilead claiming that the government researchers were responsible for the switch. Why do I say that? There’s another Gilead antiviral that was approved by the FDA after a trial showed that the duration of symptoms of the flu was reduced by taking the drug: oseltamivir, also known as Tamiflu (licensed to Roche).

If your not familiar with Tamiflu, similar to remdesevir, the drugs clinical trial results and end points were, and continue to be, heavily debated. Tamiflu reduced the duration of symptoms in clinical trials but many debate whether use of the drug reduced hospitalizations and deaths (which is more important than reducing symptoms by less then 24 hours). There have been many independent clinical studies on Tamiflu since the original trials that showed the drug didn’t reduce hospitalizations or the death. If you review annual flu deaths from the 1970s through 2019, there is no major reduction in deaths following approval of Tamiflu in 1999. In my clinic and across medicine, there is a divide of those who use the drug because they believe it works and those who don’t believe it works, but prescribe the drug on occasion, more so when patients request it (I believe Tamiflu has a strong placebo effect). Tamiflu also has common side effects such as diarrhea, vomiting and headache, which can make influenza worse for people with mild symptoms. Many medical providers prescribe antiemetics and antidiarrials with Tamiflu because of these side effects.

My point, and a point that has been discussed here and in the news, is this: remdesevir is a temporary bandaid that may provide “hope” to the country and give providers a drug to give to COVID19 patients. Reducing the duration of symptoms might get people back to work sooner (that’s debatable as well), but if the drug doesn’t reduce hospitalizations or deaths, it’s not much of treatment for future COVID19 pandemics (if the virus returns next fall, etc.)

Leronlimab can still be the breakthrough drug for COVID19 if CYDY can get the trials enrolled quickly and get the results to the FDA and published for all medical professionals to read. Additionally, leronlimab may be the drug that can be used to treat influenza. 40k-60K deaths per year in the U.S. alone, and many more worldwide, is unacceptable and I believe that in a few years from now, maybe somber, we’ll see an NIH funded trial for leronlimab in high risk patients diagnosed with influenza (young children, the elderly, and those with comorbidities). But until then, we as investors play the game of waiting for official trial data, funding and everything in between.


(4)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us